RCT | First-Line Serplulimab vs. placebo added to chemotherapy in patients with extensive-stage small cell lung cancer.
28 Sep, 2022 | 13:41h | UTCEffect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract